Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB<sub>1</sub>R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis
作者:Malliga R. Iyer、Resat Cinar、Alexis Katz、Michael Gao、Katalin Erdelyi、Tony Jourdan、Nathan J. Coffey、Pal Pacher、George Kunos
DOI:10.1021/acs.jmedchem.6b01504
日期:2017.2.9
We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducible nitric oxide synthase (iNOS). A series of 3,4-diarylpyrazolinecarboximidamides were synthesized and evaluated in CB1 receptor (CB1R) binding assays and iNOS activity assays. The novel compounds
我们报告了新型双靶化合物的设计,合成和结构活性关系,该化合物在1型大麻素受体(CB 1 R)上具有拮抗/反向激动剂活性,并且对诱导型一氧化氮合酶(iNOS)具有抑制作用。合成了一系列3,4-二芳基吡唑啉羧酰亚胺衍生物,并通过CB 1受体(CB 1 R)结合测定和iNOS活性测定进行了评估。被设计为具有有限的脑渗透能力的新型化合物引发了有效的体外CB 1 R拮抗剂活性和iNOS抑制活性。一些关键化合物显示出高的CB 1 R结合亲和力。化合物7在iNOS抑制和CB 1 R拮抗作用介导的纤维化动物模型中,已证实了有效的体内药理活性,例如通过CB 1 Rs拮抗作用介导的食物摄取减少和抗纤维化作用。